MedWatch

ALK benefits from Mylan's Epipen woes

Mylan's present difficulties in delivering its adrenalin pen, Epipen, in Britain are benefiting the Danish, allergy-focused pharmaceutical company ALK, which has increased production of its own version of the product in order to meet increasing demand. 

ALK has increased production of its adrenalin pen, Jext.

One's loss is another's gain.

The allergy-focused pharmaceutical company ALK is benefiting from the difficulties of its rival, the generic-pharmaceuticals giant Mylan, in distributing its adrenalin pen in Britain and Europe. The Danish company ALK has marketed its own version of the adrenalin pen, Jext, since 2011 – in direct competition with Mylan's Epipen.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier